# Safety, Tolerability, and Pharmacokinetics of HL-003 in Healthy Subjects

> **NCT06867393** · PHASE1 · RECRUITING · sponsor: **Shanghai Kechow Pharma, Inc.** · enrollment: 52 (estimated)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** HL-003 tablet Placeco
- **DRUG:** HL-003 tablet

## Key facts

- **NCT ID:** NCT06867393
- **Lead sponsor:** Shanghai Kechow Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-28
- **Primary completion:** 2025-08
- **Final completion:** 2025-09
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2025-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06867393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06867393, "Safety, Tolerability, and Pharmacokinetics of HL-003 in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06867393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*